Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-523 in Relapsed or Refractory Mature B-cell Neoplasms
NCT02857998Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2016
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sovleplenib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 5 more, sponsored by Hutchison MediPharma (HMP). Primary endpoint: Dose Limiting Toxicities at 28 days. Started Dec 2016; status: completed.
02
Drugs
sovleplenib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02857998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857998.